Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody.
Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation. 2001 Mar 27; 71(6):773-7.